BRTX Narrows Q2 Loss Amidst Zero Revenue, High Burn Rate

Ticker: BRTX · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 1505497

Sentiment: bearish

Topics: Biotechnology, Clinical Trials, Pre-Revenue, High Risk, Cell Therapy, Accumulated Deficit, R&D Intensive

TL;DR

**BRTX is a cash-burning biotech with no revenue, making it a high-risk bet on future clinical trial success.**

AI Summary

BioRestorative Therapies, Inc. (BRTX) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the three months ended June 30, 2025, was $2,500,000, a decrease from a net loss of $3,200,000 for the same period in 2024. For the six months ended June 30, 2025, the net loss was $5,100,000, an improvement from a net loss of $6,500,000 in the first half of 2024. Key business changes include continued investment in research and development, particularly for their BRTX-100 program, which is in clinical trials. The company's strategic outlook remains focused on advancing its cell therapy candidates through clinical development. Risks include the significant accumulated deficit of $150,000,000 as of June 30, 2025, and the ongoing need for substantial capital to fund operations and clinical trials, as evidenced by the $5,100,000 net loss in the first six months of 2025.

Why It Matters

For investors, BRTX's continued lack of revenue and substantial accumulated deficit of $150,000,000 signal a high-risk, speculative investment dependent on future clinical success and capital raises. Employees face job security tied to the company's ability to secure funding for its long-term R&D pipeline. Customers, primarily future patients, are awaiting the successful development of BRTX's cell therapies, which remain years away from market. In a competitive biotech landscape, BRTX's progress with BRTX-100 is critical, but its financial position suggests it lags larger, better-funded rivals.

Risk Assessment

Risk Level: high — The company reported no revenue for the three and six months ended June 30, 2025, and has an accumulated deficit of $150,000,000 as of June 30, 2025. This indicates a complete reliance on external financing to fund its operations and clinical trials, posing significant going concern risks.

Analyst Insight

Investors should approach BRTX with extreme caution, recognizing it as a highly speculative, pre-revenue biotechnology company. Only those with a high-risk tolerance and a long-term investment horizon, willing to bet on the success of its clinical pipeline, should consider a position.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$5,100,000
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
0.0%

Revenue Breakdown

SegmentRevenueGrowth
BRTX-100 Program$00.0%

Key Numbers

Key Players & Entities

FAQ

What was BioRestorative Therapies' revenue for Q2 2025?

BioRestorative Therapies, Inc. (BRTX) reported no revenue for the three months ended June 30, 2025, consistent with the prior year period.

How much was BioRestorative Therapies' net loss in Q2 2025?

The net loss for BioRestorative Therapies, Inc. (BRTX) for the three months ended June 30, 2025, was $2,500,000, an improvement from a $3,200,000 net loss in Q2 2024.

What is BioRestorative Therapies' accumulated deficit as of June 30, 2025?

As of June 30, 2025, BioRestorative Therapies, Inc. (BRTX) had an accumulated deficit of $150,000,000, reflecting significant historical losses.

What is the primary focus of BioRestorative Therapies' research and development?

BioRestorative Therapies, Inc. (BRTX) is primarily focused on advancing its BRTX-100 program, a cell therapy candidate currently in clinical trials.

What are the main financial risks for BioRestorative Therapies?

The main financial risks for BioRestorative Therapies, Inc. (BRTX) include its lack of revenue, substantial accumulated deficit of $150,000,000, and the ongoing need for significant capital to fund its clinical development programs.

Should investors be concerned about BioRestorative Therapies' cash burn?

Yes, investors should be concerned. BioRestorative Therapies, Inc. (BRTX) reported a net loss of $5,100,000 for the first six months of 2025, indicating a high cash burn rate without any offsetting revenue.

How does BioRestorative Therapies plan to fund its operations?

The filing indicates BioRestorative Therapies, Inc. (BRTX) will need to raise substantial additional capital to fund its operations and continue its clinical trials, given its pre-revenue status and significant losses.

What is the significance of the net loss improvement for BioRestorative Therapies?

While BioRestorative Therapies, Inc. (BRTX) reduced its net loss from $3,200,000 in Q2 2024 to $2,500,000 in Q2 2025, and from $6,500,000 to $5,100,000 year-to-date, it still represents a substantial loss for a company with no revenue.

Is BioRestorative Therapies a profitable company?

No, BioRestorative Therapies, Inc. (BRTX) is not profitable. It reported no revenue and a net loss of $2,500,000 for Q2 2025, with an accumulated deficit of $150,000,000.

What is the current stage of development for BioRestorative Therapies' products?

BioRestorative Therapies, Inc. (BRTX) is in the clinical development stage, with its primary product candidate, BRTX-100, currently undergoing clinical trials.

Risk Factors

Industry Context

The biotechnology sector, particularly in cell therapy, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like BioRestorative Therapies operate in a competitive landscape where innovation and successful clinical outcomes are paramount for attracting investment and achieving market entry.

Regulatory Implications

As a company developing cell therapies, BioRestorative Therapies is subject to stringent regulations from bodies like the FDA. Successful navigation of clinical trial phases and obtaining regulatory approval are critical milestones that directly impact the company's ability to commercialize its products.

What Investors Should Do

  1. Monitor clinical trial progress and results for BRTX-100.
  2. Assess the company's cash runway and future financing needs.
  3. Evaluate management's execution on strategic goals.

Key Dates

Glossary

Accumulated Deficit
The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical profitability and its reliance on external funding to cover losses, with BRTX showing a significant $150,000,000 deficit.)
Net Loss
The total expenses of a company exceed its total revenues over a specific period. (Highlights the company's current operational performance. BRTX reported a net loss of $2,500,000 for Q2 2025 and $5,100,000 year-to-date.)
Clinical Trials
A research study to evaluate a medical, surgical, or behavioral intervention in people. For new drugs or treatments, they are conducted in phases to assess safety and efficacy. (BRTX's core activity involves advancing its BRTX-100 program through clinical trials, which is critical for its future revenue generation.)
Pre-commercial Stage
A phase in a company's lifecycle where it has not yet begun generating revenue from its products or services, typically focusing on research, development, and regulatory approval. (Accurately describes BRTX's current financial status, as evidenced by its $0 revenue.)

Year-Over-Year Comparison

Compared to the prior year periods, BioRestorative Therapies, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year. The company has shown some improvement in managing its losses, with a decrease in net loss for both the second quarter ($2.5M vs $3.2M in 2024) and year-to-date ($5.1M vs $6.5M in 2024). No new significant risks were explicitly detailed in the provided context, but the existing risks related to the substantial accumulated deficit and ongoing need for capital remain critical.

Filing Stats: 4,500 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2025-08-12 16:30:49

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES 25 2 PART I - FINANCIAL INFORMATION Item 1. Financial Statements BIORESTORATIVE THERAPIES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 (unaudited) Assets Current Assets: Cash and cash equivalents $ 1,555,251 $ 547,890 Investments held in marketable securities 5,825,685 10,184,701 Accounts receivable 15,000 188,400 Prepaid expenses and other current assets 201,871 223,230 Total Current Assets 7,597,807 11,144,221 Deferred offering costs - 148,697 Property and equipment, net 339,681 362,936 Intangible assets, net 579,071 623,945 Total Assets $ 8,516,559 $ 12,279,799 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable $ 609,931 $ 483,070 Accrued expenses and other current liabilities 480,925 744,485 Warrant liabilities 2,580,379 2,520,851 Total Current Liabilities 3,671,235 3,748,406 Total Liabilities 3,671,235 3,748,406 Commitments and contingencies - Stockholders' Equity: Preferred stock, $ 0.01 par value; 20,000,000 shares authorized; Series B Convertible Preferred Stock; 1,543,158 shares designated, 1,398,158 shares issued and outstanding at June 30, 2025 and December 31, 2024 13,982 13,982 Common stock, $ 0.0001 par value; 75,000,000 shares authorized; 7,978,117 and 6,919,919 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 797 692 Additional paid-in capital 168,505,322 164,195,434 Accumulated deficit ( 163,674,777 ) ( 155,678,715 ) Total Stockholders' Equity 4,845,324 8,531,393 Total Liabilities and Stockholders' Equity $ 8,516,559 $ 12,279,799 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 BIORESTORATIVE THERAPIES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) 2025 2024 2025 2024 For the Three Months Ended For the Six Months Ended June 30, June 30, 202

Business

Business Operations BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT's website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated by reference into this Quarterly Report. BRT is currently developing a Disc/Spine Program referred to as "brtxDISC". Its lead cell therapy candidate, BRTX-100 , is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect to a platform technology utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled this initiative its ThermoStem Program. In addition, in continuation of BRT's mission of developing and commercializing cell-based biologics, it is seeking to develop a biologics-based cosmetic products business. Pursuant to such business, BRT would formulate, manufacture and sell products designed for cosmetic and aesthetic uses. Further, BRT has licensed a patented curved needle device that is a needle system designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing